Search results for PLD2

Showing 7 results out of 7

×

Species

Types

Compartments

Reaction types

Search properties

Species

Types

Compartments

Reaction types

Search properties

Protein (2 results from a total of 2)

Identifier: R-HSA-1498791
Species: Homo sapiens
Compartment: endoplasmic reticulum membrane
Primary external reference: UniProt: PLD2: O14939
Identifier: R-HSA-2029075
Species: Homo sapiens
Compartment: plasma membrane
Primary external reference: UniProt: PLD2: O14939

Reaction (5 results from a total of 5)

Identifier: R-HSA-1483142
Species: Homo sapiens
Compartment: endoplasmic reticulum membrane, cytosol
In the endoplasmic reticulum (ER) membrane, phospholipase D1-4,6 (PLD1-4,6) transphosphatidylates phosphatidylcholine (PC) with glycerol to displace choline (Cho) and form phosphatidylglycerol (PG). This reaction is inferred from rats, but PLD enzymes are present in humans (Hammond et al. 1995, Steed et al. 1998, Cao et al. 1997).
Identifier: R-HSA-9014294
Species: Homo sapiens
Compartment: cytosol, plasma membrane
In its GTP bound active form, plasma membrane associated RAC2 binds to the following effectors:
IQGAP1 (Meng et al. 2007)
KIAA0355 (Bagci et al. 2020: interaction tested in detail)
PAK1 (Knaus et al. 1998; Hoppe and Swanson 2004; Carstanjen et al. 2005)
PAK4 (Zhang et al. 2019; Bagci et al. 2020)
PI3K alpha (Bokoch et al. 1996)
PLD2 (Peng et al. 2011)

The following candidate RAC2 effectors have so far only been reported in the high throughput screen by Bagci et al. 2020:
ABI1 (Bagci et al. 2020)
ABI2 (Bagci et al. 2020)
BAIAP2L1 (Bagci et al. 2020)
CAV1 (Bagci et al. 2020)
CDC42 (Bagci et al. 2020)
CDC42EP1 (Bagci et al. 2020)
CDC42EP4 (Bagci et al. 2020)
DEPDC1B (Bagci et al. 2020)
DIAPH3 (Bagci et al. 2020)
DSG2 (Bagci et al. 2020)
EPHA2 (Bagci et al. 2020)
ERBIN (Bagci et al. 2020)
GIT1 (Bagci et al. 2020)
GIT2 (Bagci et al. 2020)
ITGB1 (Bagci et al. 2020)
LAMTOR1 (Bagci et al. 2020)
MCAM (Bagci et al. 2020)
MPP7 (Bagci et al. 2020)
NCKAP1 (Bagci et al. 2020)
NHS (Bagci et al. 2020)
PAK2 (Bagci et al. 2020)
RAB7A (Bagci et al. 2020)
SLITRK5 (Bagci et al. 2020)
STBD1 (Bagci et al. 2020)
STX5 (Bagci et al. 2020)
SWAP70 (Bagci et al. 2020)
TAOK3 (Bagci et al. 2020)
TFRC (Bagci et al. 2020)
TMPO (Bagci et al. 2020)
VAMP3 (Bagci et al. 2020)
VANGL1 (Bagci et al. 2020)
WAVE2 regulatory complex (interacts with subunits CYFIP1 and WASF2) (Bagci et al. 2020)

RAC2 does not bind the following RHO GTPase effectors:
ABL2 (Bagci et al. 2020)
AMIGO2 (Bagci et al. 2020)
ARAP2 (Bagci et al. 2020)
ARFGAP3 (Bagci et al. 2020)
BAIAP2 (Bagci et al. 2020)
BRK1 (Bagci et al. 2020)
DOCK1 (Bagci et al. 2020)
DOCK5 (Bagci et al. 2020)
ELMO2 (Bagci et al. 2020)
FERMT2 (Bagci et al. 2020)
HSPE1 (Bagci et al. 2020)
IL32 (Bagci et al. 2020)
JAG1 (Bagci et al. 2020)
LETM1 (Bagci et al. 2020)
NDUFA5 (Bagci et al. 2020)
NDUFS3 (Bagci et al. 2020)
PLEKHG3 (Bagci et al. 2020)
PLEKHG4 (Bagci et al. 2020)
RAPGEF1 (Bagci et al. 2020)
SHMT2 (Bagci et al. 2020)
SLC1A5 (Bagci et al. 2020)
SLITRK3 (Bagci et al. 2020)
SNAP23 (Bagci et al. 2020)
WAVE1 complex subunit WASF1 (Bagci et al. 2020)
YKT6 (Bagci et al. 2020)
Identifier: R-HSA-2029471
Species: Homo sapiens
Compartment: plasma membrane, cytosol
Phospholipase D (PLD) catalyses the hydrolysis of the membrane phospholipid, phosphatidylcholine (PC) to generate choline and metabolically active phosphatidic acid (PA) (Lennartz 1999). Pharmacological inhibition studies show that PLD participates in FCGR-mediated phagocytosis (Kusner et al. 1996). There is an increase in the activity of PLD following the activation of phagocytosis via FCGR (Kusner et al. 1999). Following activation of FCGR, PLD translocates to the plasma membrane at the phagocytic cup and generate PA. This PA can be converted to DAG through the action of phosphatidic acid phosphatase-1 (PAP-1). Thus activation of PLD may be an additional pathway leading to PKC activation.
The two isoforms PLD1 and PLD2 are both shown to be essential for the formation of phagosome at different stages. PLD1 is localized on the endosomal/lysosomal compartment and PLD2 is localized at the plasma membrane. PLD2 may be linked to phagosome formation whereas PLD1 may be involved in the focal exocytosis at the plasma membrane and also in the maturation process (Carrotte et al. 2006).
Identifier: R-HSA-9013009
Species: Homo sapiens
Compartment: plasma membrane
In its GTP bound active form, plasma membrane associated RHOA (or constitutively active RHOA mutant in the high throughput study by Bagci et al. 2020) binds to the following effectors:
ANLN (Piekny and Glotzer 2008; Budnar et al. 2019; Bagci et al. 2020)
CIT (Madaule et al. 1995; Bagci et al. 2020) and its neuron specific splicing isoform CIT 3 (Di Cunto et al. 1998)
DAAM1 (Aspenstrom et al. 2006; Higashi et al. 2008)
DIAPH1 (Otomo et al. 2005; Higashi et al. 2008; Lammers et al. 2008; Gao et al. 2009; Li and Sewer 2010; Bagci et al. 2020)
DIAPH3 (Alberts et al. 1998; Watanabe et al. 2010; Staus et al. 2011; Chen et al. 2017; Bagci et al. 2020)
IQGAP1 (Casteel et al. 2012)
PKN1 (Maesaki et al. 1999; Hutchinson et al. 2011; Hutchinson et al. 2013)
PKN2 (Hutchinson et al. 2013; Bagci et al. 2020)
PKN3 (Hutchinson et al. 2013)
PLD1 (Hammond et al. 1997; Yamazaki et al. 1999)
RHPN1 (Watanabe et al. 1996; Peck et al. 2002)
RHPN2 (Peck et al. 2002)
ROCK1 (Ishizaki et al. 1996; Leung et al. 1996; Bagci et al. 2020)
ROCK2 (Leung et al. 1996; Bagci et al. 2020)
RTKN (Reid et al. 1996; Fu et al. 2000)
SLK (Bagci et al. 2020: interaction and activation of SLK downstream of RHOA confirmed in detail)
STK10 (Bagci et al. 2020: interaction corroborated by additional experimental methods)

The following putative RHOA effectors are annotated as candidates either because of opposing findings reported by different studies or because their binding to RHOA was only shown in the context of constitutively active RHOA mutant in the high throughput screen by Bagci et al. 2020:
AAAS (Bagci et al. 2020)
ABCD3 (Bagci et al. 2020)
ACBD5 (Bagci et al. 2020)
ACTC1 (Bagci et al. 2020)
ARHGAP1 (Bagci et al. 2020)
BCR (Bagci et al. 2020)
C1QBP (Bagci et al. 2020)
CAV1 (Bagci et al. 2020)
CAVIN1 (Bagci et al. 2020)
DEPDC1B (Bagci et al. 2020)
ERBIN (Bagci et al. 2020)
FAF2 (Bagci et al. 2020)
FLOT1 (Bagci et al. 2020)
FLOT2 (Bagci et al. 2020)
FMNL3 (Bagci et al. 2020: binding to RHOA; Vega et al. 2011: no binding to RHOA)
HMOX2 (Bagci et al. 2020)
IQGAP3 (Bagci et al. 2020)
JUP (Bagci et al. 2020)
MCAM (Bagci et al. 2020)
MYO9B (Bagci et al. 2020)
PCDH7 (Bagci et al. 2020)
SCFD1 (Bagci et al. 2020)
SNAP23 (Bagci et al. 2020)
SOWAHC (Bagci et al. 2020)
STBD1 (Bagci et al. 2020)
STOM (Bagci et al. 2020)
TFRC (Bagci et al. 2020)
TJP2 (Bagci et al. 2020)
TMPO (Bagci et al. 2020)
VAMP3 (Bagci et al. 2020)
VANGL1 (Bagci et al. 2020)

RHOA does not bind the following effectors:
CCDC187 (Bagci et al. 2020)
CDC42BPA (Leung et al. 1998)
CDC42BPB (Leung et al. 1998)
CDC42EP1 (Joberty et al. 1999)
CDC42EP2 (Joberty et al. 1999)
CDC42EP3 (Joberty et al. 1999)
CDC42EP4 (Joberty et al. 1999)
CDC42EP5 (Joberty et al. 1999)
FMNL2 (Kitzing et al. 2010)
IQGAP2 (Brill et al. 1996)
KIAA0355 (Bagci et al. 2020)
PLD2 (Kodaki and Yamashita 1997)
WAS (WASP) (Aspenstrom et al. 1996)
Identifier: R-HSA-9013145
Species: Homo sapiens
Compartment: plasma membrane, cytosol
In its GTP bound active form, plasma membrane associated RAC1 binds to the following cytosolic and plasma membrane effectors:
BAIAP2 (Lewis Saravalli et al. 2013, Bagci et al. 2020)
CAV1 (Nethe et al. 2010, Bagci et al. 2020)
CDC42BPA (Schwarz et al. 2012)
CIT (Madaule et al. 1995)
CIT 3 (Di Cunto et al. 1998)
CYFIP1 (Schneck et al. 2003, Bagci et al. 2020)
FMNL1 (Yayoshi Yamamoto et al. 2000)
IQGAP1 (Kuroda et al. 1996, Pelikan Conchaudron et al. 2011)
IQGAP2 (Brill et al. 1996, Ozdemir et al. 2018)
IQGAP3 (Wang et al. 2007)
KIAA0355 (Bagci et al. 2020: interaction studied in detail)
NISCH (Reddig et al. 2005)
NOX1 complex (Cheng et al. 2006, Miyano et al. 2006, Kao et al. 2008)
NOX2 complex (Ushio Fukai et al. 2002)
NOX3 complex (Ueyama et al. 2006, Miyano and Sumimoto 2007, Kao et al. 2008)
PAK1 (Parrini et al. 2002)
PAK2 (Manser et al. 1994, Manser et al. 1995, Bagci et al. 2020)
PAK3 (Manser et al. 1995)
PAK4 (Abo et al. 1998, Bagci et al. 2020)
PAK5 (Dan et al. 2002)
PAK6 (Lee et al. 2002)
PARD6A (Qiu et al. 2000)
PI3K alpha (Bokoch et at al. 1996, Murga et al. 2002)
PKN1 (Owen et al. 2003, Modha et al. 2008)
PKN2 (Zong et al. 1999)
PLD1 (Hammond et al. 1997)
PLD2 (Hiroyama and Exton 2005)
WAVE complex (Miki et al. 1998, Suetsugu et al. 2006, Bagci et al. 2020)

The following RAC1 effectors are annotated as candidate effectors either because of opposing finding reported in different studies or because they have only been reported in the high throughput screen by Bagci et al. 2020:
ABI1 (Bagci et al. 2020)
ABL2 (Bagci et al. 2020)
AMIGO2 (Bagci et al. 2020)
ARAP2 (Bagci et al. 2020)
BAIAP2L1 (Bagci et al. 2020)
BRK1 (Bagci et al. 2020)
CDC42 (Bagci et al. 2020)
CDC42EP1 (Bagci et al. 2020: binding to activated RAC1; Joberty et al. 1999: no binding to activated RAC1)
CDC42EP4 (Bagci et al. 2020: binding to activated RAC1; Joberty et al. 1999: no binding to activated RAC1)
DEPDC1B (Bagci et al. 2020)
DIAPH3 (Bagci et al. 2020)
EPHA2 (Bagci et al. 2020)
ERBIN (Bagci et al. 2020)
FERMT2 (Bagci et al. 2020)
GIT1 (Bagci et al. 2020)
GIT2 (Bagci et al. 2020)
ITGB1 (Bagci et al. 2020)
JAG1 (Bagci et al. 2020)
LAMTOR1 (Bagci et al. 2020)
MCAM (Bagci et al. 2020)
MPP7 (Bagci et al. 2020)
NCKAP1 (Bagci et al. 2020)
NHS (Bagci et al. 2020)
PLEKHG3 (Bagci et al. 2020)
PLEKHG4 (Bagci et al. 2020)
RAB7A (Bagci et al. 2020)
SLC1A5 (Bagci et al. 2020)
SNAP23 (Bagci et al. 2020)
SWAP70 (Bagci et al. 2020)
TAOK3 (Bagci et al. 2020)
TFRC (Bagci et al. 2020)
TMPO (Bagci et al. 2020)
VAMP3 (Bagci et al. 2020)
VANGL1 (Bagci et al. 2020)
WIP WASP complex (WAS, also known as WASP, a component of the WIP WASP complex, was reported to interact with active RAC1 by Aspenstrom et al. 1996 and Vastrik et al. 1999, but no interaction has been reported between RAC1 and WIP components of the complex, WIPF1, WIPF2 or WIPF3)

Active RAC1 does not bind the following RHO GTPase effectors:
ANKLE2 (Bagci et al. 2020)
ARFGAP3 (Bagci et al. 2020)
ARMCX3 (Bagci et al. 2020)
CDC42EP2 (Joberty et al. 1999)
CDC42EP3 (Joberty et al. 1999)
CDC42EP5 (Joberty et al. 1999)
DSG2 (Bagci et al. 2020)
DIAPH1 (Higashi et al. 2008)
DOCK1 (Bagci et al. 2020)
DOCK5 (Bagci et al. 2020)
ELMO2 (Bagci et al. 2020)
FMNL2 (Block et al. 2012)
HSPE1 (Bagci et al. 2020)
IL32 (Bagci et al. 2020)
LETM1 (Bagci et al. 2020)
LMAN1 (Bagci et al. 2020)
NDUFA5 (Bagci et al. 2020)
NDUFS3 (Bagci et al. 2020)
PGRMC2 (Bagci et al. 2020)
RAPGEF1 (Bagci et al. 2020)
ROCK1 (Leung et al. 1996)
ROCK2 (Leung et al. 1996)
RTKN (Reid et al. 1996)
SHMT2 (Bagci et al. 2020)
SLK (Yamada et al. 2000)
SLITRK3 (Bagci et al. 2020)
SLITRK5 (Bagci et al. 2020)
STBD1 (Bagci et al. 2020)
STX5 (Bagci et al. 2020)
VAPB (Bagci et al. 2020)
Cite Us!